Acute myocardial infarction on the background of feminizing hormone therapy
Authors:
Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation
For correspondence: Sign in or register.
Type: Case reports
DOI:
For citation: Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Shuvaev I.P., Golubev E.P., Akildzhonov F.R. Acute myocardial infarction on the background of feminizing hormone therapy. Creative Cardiology. 2023; 17 (1): 153–9 (in Russ.). DOI: 10.24022/1997-3187-2023-17-1-153-159
Received / Accepted: 11.09.2022 / 14.02.2023
Keywords: acute myocardial infarction transgender feminizing hormone therapy
Abstract
The prevalence of the transgender population worldwide is steadily increasing. Due to the complex interplay between underlying disease, psychosocial factors, and high doses of hormone replacement therapy, transgender patients present a diagnostic and therapeutic challenge. This case presents one of such dilemmas on the example of a clinical analysis of acute transmural myocardial infarction against the background of feminizing hormone therapy. The clinical case emphasizes the need for a differential diagnostic search in young patients with complaints of pain in the heart area against the background of feminizing hormone therapy. In the diagnostic search for a probable cause, it was not possible to determine the main provoking factor for the manifestation of acute transmural myocardial infarction with a debut at an early age. An important factor now, apparently, is high-dose hormonal therapy for gender conversion, which is associated with the activation of the thrombotic cascade with further hypercoagulability and the development of a cardiovascular complication.References
- Meerwijk E., Sevelius J. Transgender population size in the united states: a meta-regression of population-based probability samples. Am. J. Public Health. 2017; 107 (2): e1–e8. DOI: 10.2105/ AJPH.2016.303578
- Abramowitz J. Hormone Therapy in Children and Adolescents. Endocrinol. Metab. Clin. North Am. 2019; 48 (2): 331–9. DOI: 10.1016/j.ecl.2019. 01.003
- The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) 2017. ESC guidelines for the management of acute myocardial infarction in pati-ents presenting with ST-segment elevation. Russian Journal of Cardiology. 2018; 5: 103–58 (in Russ.). DOI: 10.15829/1560-4071-2018-5- 103-158
- Alzahrani T., Nguyen T., Ryan A. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ. Cardiovasc. Qual. Outcomes. 2019; 12 (4): e005597. DOI: 10.1161/ CIRCOUTCOMES.119.005597
- Totaro M., Palazzi S., Castellini C. Risk of venous thromboembolism in transgender people undergoing hormone feminizing therapy: a prevalence meta-analysis and meta-regression study. Front. Endocrinol (Lausanne). 2021; 12: 741866. DOI: 10.3389/fendo.2021.741866
- Hughes L., King W., Gamarel K., Geronimus A., Panagiotou O., Hughto J. Differences in all-cause mortality among transgender and non-transgender people enrolled in private insurance. Demography. 2022; 59 (3): 1023–43. DOI: 10.1215/00703370- 9942002
- Asscheman H., T'Sjoen G., Lemaire A. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014; 46 (7): 791–5. DOI: 10.1111/and.12150
- Dutra E., Lee J., Torbati T., Garcia M., Merz C., Shufelt C. Cardiovascular implications of genderaffirming hormone treatment in the transgender population. Maturitas. 2019; 129: 45–9. DOI: 10.1016/j.maturitas.2019.08.010
- Maraka S., Singh Ospina N., Rodriguez-Gutierrez R. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2017; 102 (11): 3914-23. DOI: 10.1210/jc.2017-01643
- Aranda G., Halperin I., Gomez-Gil E. Cardiovascular risk associated with gender affirming hormone therapy in transgender population. Front. Endocrinol. (Lausanne). 2021; 12: 718200. DOI: 10.3389/fendo.2021.718200
- Kim J., Bhupathiraju S., Harrington L. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study. Menopause. 2022; 29 (3): 293-303. DOI: 10.1097/ GME.0000000000001924
- Wierckx K., Van Caenegem E., Schreiner T., Haraldsen I., Fisher A., Toye K. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the european network for the investigation of gender incongruence. J. Sex. Med. 2014; 11 (8): 1999–2011. DOI: 10.1111/jsm.12571
- Nota Nienke M., Wiepjes C., de Blok C., Gooren L., Kreukels B., den Heijer M. Ocurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019; 139 (11): 1461–2. DOI: 10.1016/j.endinu.2018.11.004
- Nokoff N., Scarbro S., Juarez-Colunga E., Moreau K, Kempe A. Health and cardiometabolic disease in transgender adults in the United States: behavioral risk factor surveillance system 2015. J. Endocr. 2018; 2 (4): 349–60. DOI: 10.1097/ MED.0000000000000064
- Seal L.J. Cardiovascular disease in transgendered people: A review of the literature and discussion of risk. JRSM Cardiovasc. Dis. 2019; 8: 2048004019880745. DOI: 10.1177/2048004019880745
- Schutte M., Kleemann R., Nota N. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS One. 2022; 17 (3): e0261312. DOI: 10.1371/journal.pone.0261312
About Authors
- Yuriy I. Buziashvili, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Head of the Clinico-Diagnostic Department; ORCID
- Elmira U. Asymbekova, Dr. Med. Sci., Leading Researcher; ORCID
- Elvina F. Tugeeva, Dr. Med. Sci., Senior Researcher; ORCID
- Igor P. Shuvaev, Cand. Med. Sci., Cardiologist; ORCID
- Evgeniy P. Golubev, Cand. Med. Sci., Cardiovascular Surgeon; ORCID
- Firdavsdzhon R. Akildzhonov, Postgraduate; ORCID